Premium
Safinamide: add‐on therapy for Parkinson's disease
Author(s) -
Chaplin Steve
Publication year - 2016
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1501
Subject(s) - medicine , levodopa , parkinson's disease , disease , adverse effect
Safinamide (Xadago) was launched in the UK in May for the treatment of adults with idiopathic Parkinson's disease as add‐on therapy to levodopa in mid‐ to latestage fluctuating patients. This article describes its mode of action, efficacy and adverse effects.